SANTA CLARA, Calif. --(BUSINESS WIRE)-- Iris Biotechnologies announces that the Japanese Patent Office has issued a notice of allowance of its Artificial Intelligence System for Genetic Analysis to be granted as a patent. This follows the issuance of a family of patents in the US, EU, Canada , Hong Kong , Australia, and New Zealand .
A critical mass of scientific knowledge, instrumentation and affordable computing power is at hand, yet a critical piece has been missing which Iris is now able to provide: smart integration of genomic, proteomic, lifestyle, family history and environmental information. Iris is poised to play a leading role in answering the unmet needs of a multi-billion-dollar market.
"Compared to when Iris Biotechnologies common stock (IRSB) was trading at $4.50 per share, the Company now has more patents worldwide and is planning to launch the first Iris Wellness Labs this summer," said Iris CEO Simon Chin . To read more about Iris Wellness services, please visit ir.irisbiotech.com under Quick Links.
About Iris Biotechnologies Inc.
Iris Biotechnologies Inc. (OTC MKTS: IRSB), unlike other life sciences companies, focuses on providing accurate, affordable precision healthcare through comprehensive analysis of the whole person inside and out. Iris offers the best approach to the treatment of cancer and other diseases through incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personalized, cost-effective healthcare and is the future of precision medicine.
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005173/en/
CONTACT: Iris Biotechnologies Inc.
Simon Chin , 408-806-7149
President and CEO
Source: Iris Biotechnologies Inc.